241 related articles for article (PubMed ID: 16361575)
1. Effect of repetitive administration of Doxorubicin-containing liposomes on plasma pharmacokinetics and drug biodistribution in a rat brain tumor model.
Arnold RD; Mager DE; Slack JE; Straubinger RM
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8856-65. PubMed ID: 16361575
[TBL] [Abstract][Full Text] [Related]
2. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer.
Charrois GJ; Allen TM
Biochim Biophys Acta; 2004 May; 1663(1-2):167-77. PubMed ID: 15157619
[TBL] [Abstract][Full Text] [Related]
3. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model.
Zhou R; Mazurchuk R; Straubinger RM
Cancer Res; 2002 May; 62(9):2561-6. PubMed ID: 11980650
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of tumor vascular priming by a nanoparticulate doxorubicin formulation.
Roy Chaudhuri T; Arnold RD; Yang J; Turowski SG; Qu Y; Spernyak JA; Mazurchuk R; Mager DE; Straubinger RM
Pharm Res; 2012 Dec; 29(12):3312-24. PubMed ID: 22798260
[TBL] [Abstract][Full Text] [Related]
5. Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection.
Ishida T; Atobe K; Wang X; Kiwada H
J Control Release; 2006 Oct; 115(3):251-8. PubMed ID: 17045355
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy.
Siegal T; Horowitz A; Gabizon A
J Neurosurg; 1995 Dec; 83(6):1029-37. PubMed ID: 7490617
[TBL] [Abstract][Full Text] [Related]
7. Comparative plasma and tissue distribution of Sun Pharma's generic doxorubicin HCl liposome injection versus Caelyx
Burade V; Bhowmick S; Maiti K; Zalawadia R; Jain D; Rajamannar T
Cancer Chemother Pharmacol; 2017 May; 79(5):899-913. PubMed ID: 28349166
[TBL] [Abstract][Full Text] [Related]
8. Liposome-mediated therapy of intracranial brain tumors in a rat model.
Sharma US; Sharma A; Chau RI; Straubinger RM
Pharm Res; 1997 Aug; 14(8):992-8. PubMed ID: 9279878
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of the EPC and HEPC sterically stabilized doxorubicin liposomes and further studies on pharmacokinetics in rats].
Yu M; Wang Y; Shu G; Zhu Z; Fang S; Wang L
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Jun; 25(3):597-9. PubMed ID: 18693438
[TBL] [Abstract][Full Text] [Related]
10. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
11. Multiple injections of pegylated liposomal Doxorubicin: pharmacokinetics and therapeutic activity.
Charrois GJ; Allen TM
J Pharmacol Exp Ther; 2003 Sep; 306(3):1058-67. PubMed ID: 12808004
[TBL] [Abstract][Full Text] [Related]
12. In vivo evaluation of doxorubicin carried with long circulating and remote loading proliposome.
Junping W; Maitani Y; Takayama K; Nagai T
Int J Pharm; 2000 Aug; 203(1-2):61-9. PubMed ID: 10967428
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv.
Cheng WW; Allen TM
J Control Release; 2008 Feb; 126(1):50-8. PubMed ID: 18068849
[TBL] [Abstract][Full Text] [Related]
14. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
15. Antivascular and antitumor activities of liposome-associated drugs.
Straubinger RM; Arnold RD; Zhou R; Mazurchuk R; Slack JE
Anticancer Res; 2004; 24(2A):397-404. PubMed ID: 15152936
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.
Lopes de Menezes DE; Pilarski LM; Allen TM
Cancer Res; 1998 Aug; 58(15):3320-30. PubMed ID: 9699662
[TBL] [Abstract][Full Text] [Related]
17. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
18. Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.
Storm G; Roerdink FH; Steerenberg PA; de Jong WH; Crommelin DJ
Cancer Res; 1987 Jul; 47(13):3366-72. PubMed ID: 3581073
[TBL] [Abstract][Full Text] [Related]
19. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model.
Roy Chaudhuri T; Straubinger NL; Pitoniak RF; Hylander BL; Repasky EA; Ma WW; Straubinger RM
Mol Cancer Ther; 2016 Jan; 15(1):84-93. PubMed ID: 26516158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
